Icon reports more expectation-beating results

Medtech, pharma and biotech development outsourcer Icon continues to beat the Street when it comes to its results. Dublin, Ireland–based Icon (Nasdaq:ICLR) said today that it earned $78.5 million, or $1.43 per share, off $455.1 million in sales for the fourth quarter ended Dec. 31, 2017 – up from $74.3 million, or $1.33 per share, in

Icon beats Street on Q2 earnings, acquires Mapi Group

Drug development provider Icon PLC (Nasdaq: ICLR) saw its stock jump about 6% in value today after announcing second-quarter earnings that beat analysts’ expectations. The Dublin, Ireland–based company, which serves the pharmaceutical, biotechnology and medical device industries, also said it has acquired the Mapi Group, which provides patient-centered health outcomes research and commercialisation. Financial terms of

Preparing for 2026: Transformation ahead for patients, payors, providers and pipelines

Vicki Anastasi/Global Head, Medical Device and Diagnostic Research/ICON plc A decade from now, value-based healthcare, enabled by wearable and electronic health record (EHR) technologies, will be revolutionizing medical device markets. Manufacturers will contend with a changing constellation of customers, from payors to clinicians and patients. It will be important to consider what outcomes they will